Journal of Atherosclerosis and Thrombosis · 2023 · 15 citations · 19 references
MedicineCardiologyImmunologyImmunopathologyInflammationInnate ImmunityAortic DiseaseCardiovascular DiseaseCoronary Artery DiseaseInflammatory SignalingIschemic Heart DiseaseAngioscopyAtherosclerosis Molecular MechanismsInflammation In Cardiovascular DiseaseInnate Immune BiomarkersInterleukin-10 To Interleukin-6 RatioNonobstructive Coronary Artery DiseasePlaque InflammationRuptured Sinus Of Valsalva
AIM: This study aimed to clarify whether cholesterol crystals (CCs) are the main trigger of innate inflammation in human spontaneously ruptured aortic plaques (SRAPs). METHODS: This study included 260 SRAPs collected during nonobstructive general angioscopy (NOGA) from 126 patients with confirmed or suspected coronary artery disease. Interleukin (IL)-6 levels in SRAPs were measured. IL-6 levels in the Valsalva sinus and femoral or brachial arteries were measured. IL-6 ratios (the IL-6 level in SRAPs and arteries divided by the IL-6 level at the Valsalva sinus at the beginning of the aorta) were calculated. Quantitative analysis of CCs was performed from SRAPs. The correlation between the count of CCs and IL-6 levels in SRAPs and that between the counts of CCs and IL-6 ratios in SRAPs were analyzed. RESULTS: The IL-6 levels in SRAPs were 3.4 [2.1, 7.2] pg/mL, and the IL-6 ratio (median [interquartile range]) in SRAPs was 1.10 [1.00, 1.26]. CCs were detected in 94 of 260 SRAPs (36%). The count of CCs was 11,590 (95% confidence interval, 2,386-30,113) per 10 mL in CC-positive samples. There was a moderate correlation between the counts of CCs and IL-6 ratios in SRAPs (r=0.49, r<0.0001), whereas there was no correlation between the count of CCs and IL-6 levels in SRAPs. The IL-6 ratios of the brachial and femoral arteries were 1.06 (95% CI, 0.99-1.20) and 1.11 (95% CI, 1.04-1.20), respectively. CONCLUSIONS: CC is the main trigger of IL-6 production through innate inflammatory response in human SRAPs in situ.
19
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell, Hajime Kono, Katey J. Rayner et al. · Nature · 2010 · 3.9K citations · Full text
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean‐Claude Tardif, Simon Kouz, David D. Waters et al. · New England Journal of Medicine · 2019 · 3K citations · Full text